Drug Profile

Research programme: Transthyretin amyloid depleter antibody - BridgeBio Pharma

Alternative Names: Transthyretin amyloid depleter antibody; TTR amyloid depleter; TTR amyloid depleter antibody

Latest Information Update: 05 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

25 Feb 2026 BridgeBio Pharma announces intention to submit IND to the US FDA in 2027
25 Jan 2026 Early research in Transthyretin-related hereditary amyloidosis in USA (Parenteral), before January 2026
12 Jan 2026 BridgeBio Pharma plans clinical trials for the treatment of Transthyretin amyloid cardiomyopathy in 2027-2028

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com